Affiliation:
1. a Department of Epidemiology, Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy;
2. b Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milano, Italy;
3. c Department of Statistics and Quantitative Methods, Section of Biostatistics, Epidemiology and Public Health, Università Milano-Bicocca, Milano, Italy
Abstract
Abstract
Learning Objectives
Evaluate the risk of cancer as well as cardiovascular and renal disease in the use of oral antidiabetics. Define and adequately quantify the effect of TZD on the risk of bladder cancer, other selected cancers, and all neoplasms.
Objective.
To clarify and quantify the effect of thiazolidinediones (TZDs; e.g., pioglitazone, rosiglitazone) on the risk of bladder cancer, other selected cancers, and overall cancer in patients with type 2 diabetes, we performed a systematic review and meta-analysis of observational studies.
Methods.
A PubMed/MEDLINE search was conducted for studies published in English up to June 30, 2012. Random-effect models were fitted to estimate summary relative risks (RR).
Results.
Seventeen studies satisfying inclusion criteria (3 case-control studies and 14 cohort studies) were considered. Use of TZDs was not associated to the risk of cancer overall (summary RR: 0.96; 95% confidence interval [CI]: 0.91–1.01). A modest excess risk of bladder cancer was reported in pioglitazone (RR: 1.20; 95% CI: 1.07–1.34 from six studies) but not in rosiglitazone (RR: 1.08; 95% CI: 0.95–1.23 from three studies) users. The RRs of bladder cancer were higher for longer duration (RR: 1.42 for >2 years) and higher cumulative dose of pioglitazone (RR: 1.64 for >28,000 mg). Inverse relations were observed with colorectal cancer (RR: 0.93; 95% CI: 0.90–0.97 from six cohort studies) and liver cancer (RR: 0.65; 95% CI: 0.48–0.89 from four studies), whereas there was no association with pancreatic, lung, breast, and prostate cancers.
Conclusions.
Adequate evidence excludes an overall excess cancer risk in TZD users within a few years after starting treatment. However, there is a modest excess risk of bladder cancer, particularly with reference to pioglitazone. Assuming that this association is real, the potential implications on the risk-benefit analysis of TZD use should be evaluated.
Funder
Italian Association for Research on Cancer
Italian Minister for University and Research
Publisher
Oxford University Press (OUP)
Cited by
112 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献